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Abstract
IMPORTANCE
Existing epidemiological evidence remains controversial regarding the association between β-genus human
papillomavirus (β-HPV) and cutaneous squamous cell carcinoma (cSCC) in immunocompetent individuals.
OBJECTIVE
We aimed to clarify this association and evaluate type-specific β-HPV involvement.
DATA SOURCES
We performed a systematic literature search of MEDLINE and EMBASE for studies in humans through June
18, 2014, with no restriction on publication date or language. The following search terms were used: “human
papillomavirus” and “cutaneous squamous cell carcinoma or skin squamous cell carcinoma or cSCC or
nonmelanoma skin neoplasms.”
STUDY SELECTION
Articles were independently assessed by 2 reviewers. We only included case-control or cohort studies, in
immunocompetent individuals, that calculated the odds ratio (OR) for cSCC associated with overall and
type-specific β-HPV.
DATA EXTRACTION AND SYNTHESIS
We first assessed the heterogeneity among study-specific ORs using the Q statistic and I 2 statistic. Then, we
used the random-effects model to obtain the overall OR and its 95% CI for all studies as well as for each type
of HPV. We also tested and corrected for publication bias by 3 funnel plot–based methods. The quality of each
study was assessed with the Newcastle Ottawa Scale.
MAIN OUTCOMES AND MEASURES
Pooled ORs and 95% CIs for overall β-HPV and HPV types 5, 8, 15, 17, 20, 24, 36, and 38 association with
skin biopsy proven cSCC. RESULTS Seventy-nine articles were assessed for eligibility; 14 studies met
inclusion criteria for the meta-analysis and included 3112 adult immunocompetent study participants with
cSCC and 6020 controls. For all detection methods, the overall association between β-HPV and cSCC was
significant with an adjusted pooled OR (95% CI) of 1.42 (1.18-1.72). As for the type-specific analysis, types
5, 8, 15, 17, 20, 24, 36, and 38 showed a significant association with adjusted pooled ORs (95% CIs) of 1.4
(1.18-1.66), 1.39 (1.16-1.66), 1.25 (1.04-1.50), 1.34 (1.19-1.52), 1.38 (1.21-1.59), 1.26 (1.09-1.44), 1.23
(1.01-1.50), and 1.37 (1.13-1.67) respectively. Our subgroup analysis in studies using only serology for HPV
detection showed a significant association between overall β-HPV and HPV subtypes 5, 8, 17, 20, 24, and 38
with an increased risk of cSCC development.
CONCLUSIONS AND RELEVANCE
This journal article is available at ScholarlyCommons: http://repository.upenn.edu/epidemiology/8
This study serves as added evidence supporting β-HPV as a risk factor for cSCC in healthy individuals. The
subgroup analysis highlights this significant association for HPV 5, 8, 17, 20, and 38, which may help to direct
future prevention efforts
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IMPORTANCE Existing epidemiological evidence remains controversial regarding the
association between β-genus human papillomavirus (β-HPV) and cutaneous squamous cell
carcinoma (cSCC) in immunocompetent individuals.
OBJECTIVE We aimed to clarify this association and evaluate type-specific β-HPV
involvement.
DATA SOURCES We performed a systematic literature search of MEDLINE and EMBASE for
studies in humans through June 18, 2014, with no restriction on publication date or language.
The following search terms were used: “human papillomavirus” and “cutaneous squamous
cell carcinoma or skin squamous cell carcinoma or cSCC or nonmelanoma skin neoplasms.”
STUDY SELECTION Articles were independently assessed by 2 reviewers. We only included
case-control or cohort studies, in immunocompetent individuals, that calculated the odds
ratio (OR) for cSCC associated with overall and type-specific β-HPV.
DATA EXTRACTION AND SYNTHESIS We first assessed the heterogeneity among study-specific
ORs using the Q statistic and I2 statistic. Then, we used the random-effects model to obtain
the overall OR and its 95% CI for all studies as well as for each type of HPV. We also tested and
corrected for publication bias by 3 funnel plot–basedmethods. The quality of each study was
assessed with the Newcastle Ottawa Scale.
MAIN OUTCOMES ANDMEASURES Pooled ORs and 95%CIs for overall β-HPV and HPV types
5, 8, 15, 17, 20, 24, 36, and 38 association with skin biopsy proven cSCC.
RESULTS Seventy-nine articles were assessed for eligibility; 14 studies met inclusion criteria
for themeta-analysis and included 3112 adult immunocompetent study participants with
cSCC and 6020 controls. For all detectionmethods, the overall association between β-HPV
and cSCCwas significant with an adjusted pooled OR (95% CI) of 1.42 (1.18-1.72). As for the
type-specific analysis, types 5, 8, 15, 17, 20, 24, 36, and 38 showed a significant association
with adjusted pooled ORs (95% CIs) of 1.4 (1.18-1.66), 1.39 (1.16-1.66), 1.25 (1.04-1.50), 1.34
(1.19-1.52), 1.38 (1.21-1.59), 1.26 (1.09-1.44), 1.23 (1.01-1.50), and 1.37 (1.13-1.67) respectively.
Our subgroup analysis in studies using only serology for HPV detection showed a significant
association between overall β-HPV and HPV subtypes 5, 8, 17, 20, 24, and 38with an
increased risk of cSCC development.
CONCLUSIONS AND RELEVANCE This study serves as added evidence supporting β-HPV as a
risk factor for cSCC in healthy individuals. The subgroup analysis highlights this significant
association for HPV 5, 8, 17, 20, and 38, whichmay help to direct future prevention efforts.
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C utaneous squamous cell carcinoma (cSCC) is oneof themost commoncancers inmen andwomenworldwide,withmore than700000newlydiagnosed cases yearly
in the United States alone, compared with less than 15000
newly diagnosed cases yearly of cervical cancer.1,2 The an-
nual incidenceof cSCChas increasedat an alarming rate in the
last 3 decades, with around 8000 attributable deaths yearly,
twice the death rate from invasive cervical cancer. Further-
more, the estimated annual cost of treating cSCC cases in the
United States is about $3.8 billion. This highlights the impor-
tant public health burden that cSCC places on our health care
system.3,4Therefore, adeeperunderstandingofcSCC’s risk fac-
tors shouldhelpus todevelopmore effectivepreventivemea-
sures, in turndecreasing thenumberofnewlydiagnosedcases
and the financial burden.
The known risk factors implicated in the development of
cSCCareUVradiationexposure, immunosuppression, and fair
skin.5 In the context of the recent increase in the ratesofnewly
diagnosed cSCC, a viral etiology has been hypothesized, with
human papillomavirus (HPV) being the major incriminated
virus.6-8Humanpapillomavirusesarea largeanddiversegroup
ofmore than 170 subtypeswith 5majorHPVgenera: α papillo-
mavirus, β papillomavirus, γ papillomavirus, μ papillomavi-
rus andνpapillomavirus.9,10 β-GenusHPV (β-HPV) is themost
detected genus in cancerous, precancerous, and normal kera-
tinocytes.Theanalysisofhumanpapillomatousskin lesionsand
their relationship to virus infections and carcinogenesis had a
slow start because they were considered a cosmetic problem
with no significant medical implications. This view gradually
changed after 1922, when Lewandowsky and Lutz described a
hereditary conditioncharacterizedbyanextensiveverrucosis,
calledepidermodysplasiaverruciformis (EV).The firstdescrip-
tion of β-HPV infection and cutaneous carcinoma was mainly
the work of Stefania Jablonska, who pointed out the potential
role of HPV 5 and 8 in thesewarts as causal factors for the sub-
sequent development of cSCC.11,12 This later led the Interna-
tional Agency of Research onCancer (IARC) to consider β-HPV
types5and8, found in90%of cSCC lesionsofEVcases, aspos-
sibly carcinogenic. Also, the increased occurrence of cSCC in
solid organ transplant recipients has been associatedwith sig-
nificantlyhigher ratesofβ-HPV.13,14More recently, theassocia-
tion of β-HPV and cSCC in immunocompetent individualswas
evaluated in multiple epidemiological case-control studies6,8
with controversial results.
The molecular pathways explaining β-HPV’s implication
in the carcinogenesis of cSCC are not yet fully clarified and
could be explained by a number ofmechanisms of action, in-
cluding the following 3 pathways: (1) Increased susceptibility
toUV-inducedoncogenesis in transgenicmiceexpressingHPV
type 38 E6 andE7 oncoproteins15-17; (2) HPV type 8 E6 oncop-
rotein’s capacities to inhibit the PDZ (Psd95-DlgA-ZO1) do-
mainprotein syntenin-2, a critical element in the control of vi-
ral oncogenic potential (the downstream pathway for
syntenin-2 remains to be fully understood)18,19; and (3) β-HPV
types 5, 8, 20, and 38 through E2, 6, and 7 oncoprotein in-
crease thequantityof stemcell–like cells availableduringearly
carcinogenesis, thus enabling the persistence and accumula-
tionofDNAdamagenecessarytogeneratemalignantstemcells.
These pathways are only a fewof themanyplausiblemolecu-
larmechanisms for type-specificβ-HPV involvement in the ini-
tiation and progression of the onocogenic process in cSCC.
However, type-specific β-HPV epidemiological evidence re-
mains controversial. Thus, theprimary endpoint of thismeta-
analysis is to evaluate the existing epidemiological data on
type-specific β-HPVassociationwith cSCC in immunocompe-
tent individuals.
Methods
Databases and Search Strategy
Wesystematicallysearchedforstudies inhumansthroughJune
18, 2014, with no language restrictions or specified start date.
WesearchedtheMEDLINEandEMBASEdatabasesusingthefol-
lowingsearch terms:“humanpapillomavirusorHPVorβ-HPV”
and“cutaneoussquamouscell carcinomaorskinsquamouscell
carcinomaor cSCCor nonmelanoma skin neoplasms.” The ini-
tial inquiry was conducted by one of us (J.C.) and indepen-
dentlyverifiedby theuniversitymedical reference librarian. In
addition, to ensure comprehensiveness, we examined the ref-
erence lists from retrieved articles for supplementary relevant
studies. The results were uploaded to Mendeley, a citation
database program for review and selection.
Eligibility Criteria
Eligibilitywas restricted to studies,withhuman immunocom-
petent participants only, that examined the association be-
tweenHPV and cSCC development as primary episode. Stud-
ies were excluded if their outcome of interest was the
development of melanoma, cutaneous basal cell carcinoma,
anogenital cSCC, or recurrent cSCC. As for studydesign, case-
controls andcohorts of at least 40patientswere eligible for in-
clusion,whileweexcludedabstracts, letters to theeditor, case
Figure 1. FlowDiagram of Systematic Literature Search
for theMeta-analysis
916 Records identified and screened 
through database search
14 Records (studies) included in 
the meta-analysis
8 Records identified through
reference lists
79 Full-text articles assessed for
eligibility and their reference
lists examined for relevant articles
837 Records excluded based
on title and abstract
73 Records excluded
67 Did not meet inclusion criteria
1 Duplicate study population
5 Did not report ß-HPV or
ß-HPV subtype adjusted OR
β-HPV indicates β human papillomavirus; OR, odds ratio.
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reports, reviewarticles, case-controls (<20cases and<20con-
trols), andcohort studies (<40patients). Studies including less
than 40 patients were excluded, because they lacked statisti-
cally significantpower.Furthermore, studiesnot reporting the
associated risk for at least 2 of the HPV subtypes 5, 8, 15, 17,
20, 24, 36, and 38 were excluded from the analysis. To be in-
cluded in our analysis, studies had to report type-specific
β-HPV odds ratio (OR) or relative risk (RR) with 95% CIs. Re-
strictionswere not placed on themethodof detection ofHPV.
Selection Process
Two of us (J.C.) and (A.S.) independently reviewed the titles
and abstracts of the previously searched databases. Based on
the prespecified selection criteria, both authors indepen-
dently identified studies.Disagreementswere resolvedbydis-
cussion with a prior agreement that any unsettled conflict
would be determined by a third author (A.G.R.).
Data collection forms were used by both authors to ex-
tract the required data from eligible studies. Then both au-
thors assessed extracted studies for duplication by compar-
ingauthors’ names,datesofpublication, andpopulation sizes.
Both authors were unblinded to the studies’ authors’ names,
population sizes, journals of publication, and locations.
Data Extraction
Primary outcome measures were ORs with the correspond-
ing 95% CIs for the association of β-HPV and primary epi-
sodesof cSCC.We identified theORs reflecting thegreatestde-
gree of adjustment for possible confounding factors. The
adjusted ORs with 95% CIs for overall β-HPV, HPV types 5, 8,
15, 17,20,24,36,and38wereextracted,whenapplicable.Other
data of interest included study general information: first au-
thor name, year of publication, location, and estimated lati-
tudewhere the studypopulationwasenrolled. Informationon
Table. Characteristics of StudiesMeeting Search Inclusion Criteria
Source
Design and
Population
Multicenter/
Latitude
β-HPV Detection Methods/
Subtypes
Newcastle-Ottawa Score/
Adjustment
Masini et al,20 2003 Case-control
Cases: 46
Controls: 84
No/41.54° N ELISA serology
HPV types 8,15, 36
7
Adjusted for age, sex, eye color, and history
of lifetime exposure to sunlight
Feltkamp et al,11 2003 Case-control
Cases: 161
Controls: 386
No/52.16° N ELISA serology
HPV types 5, 8, 15, 20, 24, 38
6
Adjusted for age and sex
Karagas et al,21 2006 Case-control
Cases: 252
Control: 461
No/44° N Multiplex serology
HPV types 5, 8, 15, 20, 24, 36,
38 and overall β-HPV
9
Adjusted for age, sex, and skin sensitivity
Casabonne et al,22 2007 Case-control
Cases: 39
Controls: 80
No/51.7° N Multiplex serology
HPV types 5, 8, 15, 17, 20, 24,
36, 38
8
Adjusted for age, sex, and region of
residence
Waterboer et al,23 2008 Case-control
Cases: 43
Controls: 77
No/41.54° N Multiplex serology
HPV types 5, 8, 15, 17, 20, 24,
36, 38, and overall β-HPV
8
Adjusted for age, sex, eye color, and history
of lifetime sun exposure
Bouwes Bavinck et al,24 2010 Case-control
Cases: 689
Controls: 845
Yes/NA Multiplex serology
HPV types: 5, 8, 15, 17, 20, 24,
36, 38
EBH DNA by PCR
HPV types: 5, 8, 20, 24, 36
9
Adjusted for age and sex
Karagas et al,25 2010 Case-control
Cases: 663
Controls: 805
No/40° N Multiplex serology
HPV types 5, 8, 15, 17, 20, 24,
36, 38, and overall β-HPV
9
Adjusted for age, sex, level of education,
cigarette smoking, skin sensitivity, and
number of lifetime painful sunburns
Plasmeijer et al,26 2011 Cohort: 1311
cSCC newly
diagnosed: 150
No/26° S Multiplex serology
HPV types 5, 8, 15, 20, 24, 36,
38, and overall β-HPV
8
Adjusted for age and sex; used Cox
proportional hazards
Andersson et al,27 2012 Cohort: 850 000
Cases: 633
Controls: 633
Yes/60° N Multiplex serology
HPV types 5, 8, 15, 17, 20, 24,
36, 38 and overall β-HPV
9
Adjusted age, sex and country
Struijk et al,28 2006 Case-control
Cases: 64
Controls: 57
No/26° S ELISA Serology: HPV types 8,
15, 24 and overall β-HPV
EBH DNA by PCR: HPV types 5,
8, 15, 20, 24, 36, 38 and
overall β-HPV
7
Adjusted for age and sex
Iannacone et al,29 2012 Case-control
Cases: 173
Controls: 300
No/28° N Multiplex serology
HPV types 5, 8, 15, 17, 20, 24,
36, 38 and overall β-HPV
8
Adjusted for age and sex
Struijk et al,30 2003 Case-control
Case: 155
Control: 371
No/52.16° N EBH DNA by PCR
HPV types 5, 8, 15, 20, 24, 38
7
Adjusted for age and sex
Termorshuizen et al,31 2004 Case-control
Cases: 156
Controls: 320
No/52.16° N ELISA serology
HPV types 5, 8, 15, 20
EBH DNA by PCR: HPV types 5,
8, 15, 20
6
Adjusted for age and sex
Iannacone et al,32 2014 Case-control
Cases: 168
Controls: 290
No/28° N EBH DNA by PCR
HPV types 5, 8, 15, 20, 24, 36,
38 and overall β-HPV
8
Adjusted for age, sex, education, hair color
sunlight exposure, tanning ability, and
ever-smoking status
Abbreviations: β-HPV indicates β human papillomavirus; EBH, eyebrow hair.
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studydesign, population size and characteristics, themethod
of HPV detection, and the number of β-HPV subtypes ana-
lyzed was also collected. In certain circumstances when re-
quired data were not reported, authors corresponded with
study authors via email.
Assessment of Bias Risk
Two of us (A.S. and J.C.) independently used the Newcastle-
OttawaScale (NOS) for assessing the individual quality of each
study.We used ORs to approximate RR given the rare disease
assumption.We first assessed theheterogeneity amongstudy-
specificORsusing theQ statistic and I2 statistic.Wealso tested
andcorrected forpublicationbiasby3 funnelplot–basedmeth-
ods: the Egger test, the Begg test, and the trim & fill method.
Statistical Analysis
The meta-analysis was performed on qualifying studies that
had reported adjusted ORs of the association between global
and type-specific β-HPV with cSCC regardless of the detec-
tion method. As for the subgroup analyses, they were re-
stricted to studies using seroprevalence detected by multi-
plexserologyorenzyme-linked immunosorbentassay (ELISA).
The adjusted ORs with 95% CIs were identified based on the
meta-analysis results. Random-effects method was used to
pool theORs and 95%CIs. All study analyseswere performed
using the R (R Development Core Team, 2008) and metafor
package (Wolfgang Viechtbauer, 2010).
Results
Study Screening
The literature search of the MEDLINE and EMBASE databases
yielded916articles.After reviewof the titles andabstracts, 837
articleswereexcludedfor lackofadherence toour inclusioncri-
teria.Wereviewedthe full textof theselected79articlesandas-
sessed their reference lists for relevantpublications, retrieving
8additionalpublications.Basedonthis review,weexcluded67
publications fornonadherencewith the inclusioncriteria. Fur-
thermore, 1 publicationwasexcluded fordataoverlapwithan-
otherstudy,andweincludedtheonewiththehighestadjustment
forOR in themeta-analysis.Wealsoexcluded5publications for
not providing the associated risk of β-HPV subtypes, based on
our correspondencewith the authors. The flowdiagramof the
systematic literature review is illustrated in Figure 1.
Study Characteristics
The studies included in ourmeta-analysis comprised 12 case-
control studies and 2 cohort studies (Table).11,20-32 Publica-
tionyears ranged from2003 to 2014,withdata collected from
as late as 1992. All studies included adult immunocompetent
participants,males and females of all ages, a total of 3112 cases
and6020 controls. Our subgroup analysis comprised 12 stud-
ies thatexclusivelyusedserologyas theHPVdetectionmethod
and included 2789 cases and 5359 controls. Because UV light
exposure is a major risk factor for cSCC and has been impli-
cated as a cofactorwith β-HPV in the initiation of carcinogen-
esis in multiple molecular models, we evaluated the latitude
ofeachstudyregion.33Wedeterminedthat 11 studieswerecon-
ducted in the northern hemisphere between estimated lati-
tudes 40° N to 60° N, while only 2 studies were conducted in
the southernhemisphere at an estimated latitude of 26° S. All
included studies assessed cSCC as primary outcome in both
controls and cases by skin biopsy pathological evaluation. All
14 studies adjusted for ageandsexwhencalculating theβ-HPV
and cSCC associatedORs. Only 8 studies also adjusted for 1 or
moreof the following: skin sensitivity, regionof residence, eye
color, number of lifetime painful sun burns, smoking history,
or lifetimeexposure to sunlight.Themostuseddetection tech-
niquefordifferent typesofHPVwasserologybymultiplexpoly-
merase chain reaction (PCR) (8 studies); the ELISA assay was
used in4 studies andeyebrowhairDNA in5 studies. ELISA se-
rology is a less sensitive and specificmethod, comparedwith
multiplex serology, andwasusedonly in studiespublishedbe-
tween2003 and2006whenmultiplex serologywasnot read-
ily available. Serology is a highly cost-effective HPV detec-
tion method, because it allows for large-scale studies as well
as tracking a population over time for analyses in HPV infec-
tions. Previous studies32,34 have shown acceptable compara-
bility in sensitivity betweenβ-HPVcollected by eyebrowhair,
serology, and surgical biopsy. The selection of the β-HPV sub-
types included inbothourmeta-analysis and subgroupanaly-
sis was based on the number of studies evaluating each sub-
type: β-HPV 8 and 15 (13 studies); β-HPV 5, 20, 24, and 38 (12
studies); β-HPV36 (10 studies); and β-HPV 17 (7 studies). HPV
type17 isonesubtypeof interest thatwasnotevaluated inmost
studies. Additional information and extracted data from the
included studies are presented in eTable 1 in the Supplement.
Study Quality
Quality assessment was performed using the Newcastle
Ottawa scale, which is specifically used for nonrandomized
studies and has been endorsed by the Cochrane collabora-
tion.We adequately used the version for case-control studies
or cohort studies as applicable, addressing subject selection,
study comparability, and the assessment of outcomeor expo-
sure.NOSscores from6to9(9beingthehighestpossiblescore),
with amean of 7.8, median andmode of 8. All studies earned
a star for comparability with regard to age and sex adjust-
ment. Eight studies received an additional star for compara-
bility, because they also adjusted for skin sensitivity, region
of residence, or lifetime exposure to sunlight. A summary of
the included study evaluation as assessed using the NOS is
shown eTable 2 in the Supplement.
Publication Bias
Publication bias was not detected for the pooled studies, or
the subgroup analysis studies using the Egger test35 and the
Begg test.36 We also conducted sensitivity analyses on both
the pooled studies and the subgroup data sets to evaluate
the potential impact of publication bias on the conclusions.
We specifically applied the trim and fill method to evaluate
the subgroup analysis data set and imputed 5 studies.37 The
corrected ORs remained similar to the uncorrected ones,
suggesting that the impact of the publication bias for this
subgroup is small.
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Figure 2. Forest Plot for the Studies on the Association of HPV 5, 8, 15, 17, and 20With cSCC
OR (95% CI)
101.00.1
Cases/Controls, No.Study, year Positive, % RR (95% CI) Favors Association Favors No Association
1.40 (1.18-1.66)
1.39 (1.16-1.66)
HPV-5 (I2: 25%)
645/807Bouwes Bavinck et al,24 2010 16.90/9.05 2.05 (1.49-2.82)
675/829Bouwes Bavinck et al,24 2010 29.04/24.25 1.28 (1.02-1.61)
168/290Iannacone et al,32 2014 24.40/17.24 1.19 (0.66-2.15)
173/300Iannacone et al,29 2012 20.23/12.67 1.68 (0.95-2.97)
43/45Struijk et al,28 2006 18.60/24.44 0.59 (0.16-2.19)
633/NAAndersson et al,27 2012 10.74/NA 1.20 (0.82-1.75)
150/NAPlasmeijer et al,26 2011 9.33/NA 1.00 (0.54-1.84)
663/805Karagas et al,25 2010 6.49/5.09 1.45 (0.90-2.34)
43/77Waterboer et al,23 2008 27.91/28.57 0.60 (0.21-1.75)
39/80Casabonne et al,22 2007 12.82/20.00 0.60 (0.14-2.55)
252/461Karagas et al,21 2006 11.11/6.72 1.80 (1.02-3.17)
160/333Feltkamp et al,11 2003 1.25/0.30 2.60 (0.21-32.83)
81/212Struijk et al,30 2003 44.44/22.17 1.90 (1.03-3.50)
HPV-8 (I2: 53%)
645/807Bouwes Bavinck et al,24 2010 39.53/28.00 1.68 (1.35-2.10)
675/829Bouwes Bavinck et al,24 2010 28.44/24.37 1.23 (0.98-1.55)
168/290Iannacone et al,32 2014 17.26/12.07 1.09 (0.55-2.17)
72/203Struijk et al,30 2003 37.50/18.72 1.80 (0.94-3.46)
173/300Iannacone et al,29 2012 36.42/23.00 1.80 (1.14-2.84)
37/36Struijk et al,28 2006 5.41/5.56 0.44 (0.05-3.98)
47/46Struijk et al,28 2006 29.79/4.35 9.30 (1.90-45.56)
633/NAAndersson et al,27 2012 23.70/NA 1.00 (0.78-1.27)
150/NAPlasmeijer et al,26 2011 36.67/NA 1.10 (0.80-1.51)
663/805Karagas et al,25 2010 19.16/15.28 1.45 (1.07-1.96)
43/77Waterboer et al,23 2008 37.21/16.88 1.20 (0.51-2.84)
39/80Casabonne et al,22 2007 23.08/20.00 1.10 (0.40-3.01)
252/461Karagas et al,21 2006 16.27/14.75 1.20 (0.80-1.80)
160/333Feltkamp et al,11 2003 4.38/0.30 14.70 (1.60-135.02)
46/84Masini et al,20 2003 56.52/32.14 3.20 (1.30-7.89)
HPV-15 (I2: 50%)
645/807Bouwes Bavinck et al,24 2010 30.39/22.80 1.48 (1.17-1.87)
675/829Bouwes Bavinck et al,24 2010 37.04/29.92 1.38 (1.11-1.71)
168/290Iannacone et al,32 2014 5.95/5.86 0.94 (0.35-2.54)
71/195Struijk et al,30 2003 36.62/15.38 2.50 (1.30-4.80)
173/300Iannacone et al,29 2012 28.90/25.33 0.93 (0.58-1.49)
36/35Struijk et al,28 2006 2.78/2.86 0.64 (0.04-10.61)
43/47Struijk et al,28 2006 23.26/6.38 3.80 (0.91-15.83)
633/NAAndersson et al,27 2012 20.70/NA 1.10 (0.85-1.42)
150/NAPlasmeijer et al,26 2011 25.33/NA 1.00 (0.68-1.46)
663/805Karagas et al,25 2010 22.02/16.65 1.49 (1.11-2.00)
43/77Waterboer et al,23 2008 41.86/24.68 2.80 (1.10-7.11)
39/80Casabonne et al,22 2007 10.26/18.75 0.50 (0.12-2.06)
252/461Karagas et al,21 2006 10.32/8.89 1.30 (0.77-2.20)
160/333Feltkamp et al,11 2003 4.38/2.10 1.20 (0.40-3.60)
79/84Masini et al,20 2003 62.03/47.62 0.40 (0.19-0.85)
HPV-20 (I2: 14%)
645/807Bouwes Bavinck et al,24 2010 20.00/12.76 1.71 (1.29-2.27)
675/829Bouwes Bavinck et al,24 2010 26.37/19.9 1.44 (1.13-1.84)
168/290Iannacone et al,32 2014 8.33/6.21 1.33 (0.53-3.33)
96/254Struijk et al,30 2003 53.12/35.04 1.70 (1.00-2.89)
173/300Iannacone et al,29 2012 29.48/21.00 1.41 (0.88-2.26)
46/40Struijk et al,28 2006 23.91/15.00 0.86 (0.20-3.70)
633/NAAndersson et al,27 2012 20.70/NA 1.20 (0.90-1.60)
150/NAPlasmeijer et al,26 2011 11.33/NA 0.60 (0.33-1.10)
663/805Karagas et al,25 2010 19.76/15.16 1.45 (1.08-1.95)
43/77Waterboer et al,23 2008 30.23/29.87 0.90 (0.37-2.20)
39/80Casabonne et al,22 2007 23.08/21.25 1.10 (0.41-2.96)
252/461Karagas et al,21 2006 9.92/6.07 1.70 (0.93-3.10)
160/333Feltkamp et al,11 2003 5.00/2.10 2.20 (0.74-6.58)
HPV-17 (I2: 0%)
1.25 (1.04-1.50)
1.38 (1.21-1.59)
1.34 (1.19-1.52)
645/807Bouwes Bavinck et al,24 2010 31.78/23.54 1.51 (1.20-1.91)
675/829Bouwes Bavinck et al,24 2010 17.33/15.92 1.11 (0.84-1.46)
168/290Iannacone et al,32 2014 22.02/14.48 1.23 (0.67-2.26)
173/300Iannacone et al,29 2012 35.26/25.67 1.59 (1.02-2.48)
633/NAAndersson et al,27 2012 23.06/NA 1.20 (0.90-1.60)
663/805Karagas et al,21 2006 20.21/16.40 1.37 (1.02-1.84)
43/77Waterboer et al,23 2008 46.51/27.27 2.60 (1.02-6.60)
39/80Casabonne et al,22 2007 20.51/15.00 1.40 (0.48-4.06)
The squares and horizontal lines correspond to the study-specific odds ratios (ORs) and 95% CIs. The diamond represents the pooled OR and 95% CI of the
overall population. The vertical dashed line indicates the overall pooled OR of 1.33. cSCC, cutaneous squamous cell carcinoma; HPV, human papillomavirus;
NA, not available; OR, odds ratio; RR, relative risk.
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Meta-analysis
Type-Specific β-HPV AssociationWith cSCC
Ourmeta-analysis comprised a total of 14 studies (3112 cases;
6020controls). In thepooledanalysis, overall β-HPV–cSCCas-
sociation was significant with an adjusted pooled OR of 1.4
(95% CI, 1.2-1.7). For the type-specific analysis, types 5, 8, 15,
17, 20, 24, 36, and38 showeda significant associationwith ad-
justed pooledORs of 1.4 (95%CI, 1.2-1.7), 1.4 (95%CI, 1.2-1.7),
1.2 (95% CI, 1.0-1.5), 1.3 (95% CI, 1.2-1.5), 1.4 (95% CI, 1.2-1.6),
1.3 (95% CI, 1.1-1,4), 1.2 (95% CI, 1.0-1.5), and 1.4 (95% CI, 1.1-
1.7) respectively (Figure 2 and Figure 3). A random-effects
modelwasusedbecauseheterogeneitywas identified among
the 13 studies. Visual inspectionof the funnel plot revealedno
publicationbias, later confirmedbytheBeggadjustedrankcor-
relation test (Figure 4). The funnel plots and their respective
Beggadjusted rankcorrelation tests are represented in supple-
ment eFigures 1-9 in the Supplement.
Type-Specific β-HPV AssociationWith cSCC: Seroprevalence Only
Our subgroup meta-analysis comprised a total of 12 studies
(2789 cases; 5359 controls). The pooled analysis of the over-
all β-HPVassociationwith cSCCwas significant,with adjusted
Figure 3. Forest Plot for Studies on the Association Between HPV 24, 36, and 38, and β-HPV and cSCC
OR (95% CI)
101.00.1
Cases/Controls No.Study, year Positive, % RR (95% CI)
1.26 (1.09-1.44)
1.23 (1.01-1.50)
HPV-24 (I2: 14%)
645/807Bouwes Bavinck et al,24 2010 22.02/15.24 1.57 (1.20-2.05)
675/829Bouwes Bavinck et al,24 2010 36.59/32.69 1.19 (0.96-1.47)
168/290Iannacone et al,32 2014 20.83/12.76 1.11 (0.58-2.12)
44/41Struijk et al,28 2006 20.45/17.07 0.78 (0.19-3.15)
41/48Struijk et al,28 2006 19.51/8.33 2.60 (0.70-9.68)
633/NAAndersson et al,27 2012 10.43/NA 0.90 (0.61-1.32)
150/NAPlasmeijer et al,26 2011 14.67/NA 0.80 (0.50-1.29)
663/805Karagas et al,25 2010 12.67/10.06 1.53 (1.07-2.18)
43/77Waterboer et al,23 2008 37.21/27.27 1.40 (0.59-3.33)
39/80Casabonne et al,22 2007 12.82/20.00 0.50 (0.12-2.06)
252/461Karagas et al,21 2006 7.14/6.29 1.20 (0.63-2.30)
160/333Feltkamp et al,11 2003 13.12/6.61 1.50 (0.76-2.95)
84/221Struijk et al,30 2003 46.43/25.34 1.40 (0.78-2.52)
HPV-36 (I2: 42%)
645/807Bouwes Bavinck et al,24 2010 15.81/9.91 1.71 (1.25-2.34)
675/829Bouwes Bavinck et al,24 2010 41.78/33.29 1.44 (1.17-1.77)
168/290Iannacone et al,32 2014 6.55/7.59 0.66 (0.26-1.68)
173/300Iannacone et al,29 2012 23.12/17.33 1.13 (0.68-1.89)
633/NAAndersson et al,27 2012 12.95/NA 1.10 (0.80-1.51)
150/NAPlasmeijer et al,26 2011 10.67/NA 0.70 (0.42-1.16)
633/805Karagas et al,25 2010 8.90/7.20 1.49 (0.99-2.25)
43/77Waterboer et al,23 2008 32.56/24.68 1.60 (0.61-4.18)
39/80Casabonne et al,22 2007 15.38/16.25 0.80 (0.22-2.94)
252/461Karagas et al,21 2006 4.37/5.64 0.80 (0.38-1.70)
46/84Masini et al,20 2003 19.57/8.33 2.80 (0.79-9.90)
HPV-38 (I2: 60%)
645/807Bouwes Bavinck et al,24 2010 37.67/24.91 1.82 (1.46-2.27)
675/829Bouwes Bavinck et al,24 2010 27.70/26.06 1.09 (0.87-1.37)
168/290Iannacone et al,32 2014 32.74/17.93 1.84 (1.04-3.25)
95/256Struijk et al,30 2003 52.63/35.55 1.50 (0.89-2.52)
173/300Iannacone et al,29 2012 24.28/24.67 0.94 (0.58-1.52)
43/49Struijk et al,28 2006 18.60/30.61 0.32 (0.09-1.17)
633/NAAndersson et al,27 2012 20.54/NA 1.30 (1.00-1.69)
150/NAPlasmeijer et al,26 2011 32.00/NA 0.90 (0.61-1.32)
663/805Karagas et al,25 2010 18.70/12.05 1.74 (1.27-2.39)
43/77Waterboer et al,23 2008 48.84/27.27 3.00 (1.17-7.70)
39/80Casabonne et al,22 2007 25.64/17.50 1.50 (0.52-4.35)
252/461Karagas et al,21 2006 13.49/10.85 1.30 (0.80-2.11)
160/333Feltkamp et al,11 2003 5.62/2.70 3.00 (1.09-8.29)
HPV-genus β (I2: 45%)
1.37 (1.13-1.67)
1.42 (1.18-1.72)
168/290Iannacone et al,32 2014 86.90/73.45 1.68 (0.88-3.20)
173/300Iannacone et al,29 2012 73.41/60.33 1.93 (1.23-3.02)
63/57Struijk et al,28 2006 44.44/40.35 0.93 (0.43-2.01)
54/52Struijk et al,28 2006 37.04/13.46 3.90 (1.41-10.78)
NA/NAAndersson et al,27 2012 NA/NA 1.30 (1.05-1.62)
150/NAPlasmeijer et al,26 2011 70.67/NA 1.00 (0.71-1.41)
663/805Karagas et al,25 2010 53.09/45.84 1.30 (1.04-1.62)
NA/NAWaterboer et al,23 2008 NA/NA 3.30 (1.23-8.89)
252/461Karagas et al,21 2006 32.54/24.73 1.50 (1.04-2.17)
173/300Iannacone et al,29 2012 20.81/12.33 1.63 (0.93-2.86)
Random-effects model using DerSimonian-Laird 1.33 (1.26-1.41)
Favors Association Favors No Association
The squares and horizontal lines correspond to the study-specific odds ratios (ORs) and 95% CIs. The diamond represents the pooled OR and 95% CI of the
overall population. The vertical dashed line indicates the overall pooled OR of 1.33. cSCC, cutaneous squamous cell carcinoma; HPV, human papillomavirus;
NA, not available; OR, odds ratio; RR, relative risk.
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pooledORsof 1.4 (95%CI, 1.2-1.8), an increasedassociated risk
of 45% for cSCC development. In respect to the type-specific
pooled analysis, types HPV 5, 8, 17, 20, 24, and 38 were sig-
nificantly associated with increased risk of cSCC; the ad-
justed pooled ORs were 1.4 (95% CI, 1.1-1.8), 1.5 (95% CI, 1.2-
1.8), 1.4 (95% CI, 1.2-1.6), 1.3 (95% CI, 1.1-1.6), 1.3 (95% CI, 1.0-
1.6), and 1.4 (95% CI, 1.1-1.8), respectively. Human
papillomavirus 15 and 36 did not show any significant in-
creased risk for cSCC with respective adjusted pooled OR of
1.1 (95% CI, 0.9-1.5) and 1.11 (95% CI, 0.9-1.4) (Figure 5 and
Figure 6). Heterogeneitywas identified among the 12 studies.
The funnel plots and their respective Begg adjusted rank cor-
relation tests are represented in eFigures 10 through 21 in
Supplement 2.
Discussion
This pooled analysis included a large data sample of case-
control and cohort studies evaluating the association between
type-specificβ-HPVandcSCC.The findings suggest thatβ-HPV
is associatedwith a42% increase in the riskof cSCCamong im-
munocompetent individuals. This analysis highlights specifi-
cally types 5, 8, 15, 17, 20, 24, 36, and38,with an associated in-
creased riskof40%,39%,25%,34%,38%,26%,23%,and36%,
respectively. Notably, to our knowledge, this study is the larg-
est to evaluate the type-specific β-HPVassociated riskof cSCC.
Our subgroup analysis showed similar results with the excep-
tion of HPV type 15. In concordance with our pooled analysis,
Aldabagh et al7 performed an extensive meta-analysis evalu-
ating the association of cSCC and β-HPV in both immunocom-
promisedandhealthy individuals, restrictedtobiopsyPCRHPV
detection, and that suggested an increased risk of cSCCassoci-
ated with HPV. Their analysis was not restricted to immuno-
competent individuals and includedonly studies using biopsy
specimens with PCR-based detection of HPV, with significant
evidence of statistical heterogeneity in the included studies. A
major source of heterogeneity in their analysis was the inclu-
sionof10studies thatdidnotstrictlyaccount forcutaneousHPV
subtypes.Furthermore, the resultsdidnotaccount for theHPV
type-specific associations, which represents another limita-
tion to their findings.
Moreover, a concordance exists between our epidemio-
logical HPV type-specific findings and the established type-
specificmolecularexplanationsofHPVmechanismincSCCcar-
cinogenesis. Specifically, the E6 proteins of HPV 5 and 8 are
known to inhibit the transforming growth factor β (TGFβ) sig-
naling pathway throughdegradation of the SMAD3 transcrip-
tion factor.38,39Apathway thatnormallyplaysanessential role
in the cell cycle, which could negatively affect viral DNA rep-
lication and cell transformation. Also, HPV 5 and 8 E6 pro-
teins induce the recruitment of MAML1, which represses the
cutaneous tumor-suppressive Notch signaling pathway, fa-
voring RAS oncogene.40,41 This in turn can upregulate AP1-
activatingWnt5asignaling inkeratinocytes, a classical skincar-
cinogenesis pathway.15,42 Finally, HPV 5 and 8 E6 expression
increases the carcinogenic potential ofUV-B exposure bypro-
motingp300degradation, thus increasing thyminedimerper-
sistence and UV-induced double-strand breaks.18 However,
HPV 20 has been shown to upregulate the p16INK4a and
Akt–PI3K pathway, interfering with the cell cycle involved in
progression to basal cell carcinoma. It is also known that the
E6 proteins of HPV 20 can prevent UV-treated keratinocytes
from undergoing apoptosis,15,16,38,43 while HPV38 E7 can de-
grade pRb increasing the lifespan of human keratinocytes by
deregulating the cell cycle.15,44,45 In addition, the activation
of nuclear factor kappa beta is believed to protect β-HPV im-
mortalized human keratinocytes against tumor necrosis fac-
tor (TNF)andUV-mediatedapoptosis.46Amongall of the iden-
tified HPV types in our pooled analysis, only HPV 17 E7 binds
to UBR4, the effect of this interaction contributes to cellular
transformation and anchorage independent growth.41 Inter-
estingly the recent effort byCohenet al,47 evaluatingBRAF in-
duced-cSCC, highlighted HPV 17 as the most frequently iso-
lated genotype. Molecular evidence also supporting the
involvementofβ-HPV incSCCcarcinogenesis is the recentdis-
covery of the rs7208422 polymorphism in the EVER2 gene,
whichwasassociatedwithan increased riskof cSCC inhealthy
individuals who did not have EV.48 Previously, it was known
that the homozygous mutations in EVER2 genes cause EV,
which in turn leads to thedevelopmentof cSCCassociatedwith
β-HPV infections.EVER2 loss facilitates activation of theHPV
5 long control region through a JNK-dependent pathway
facilitating HPV replication and cSCC development.49
Quality of the Evidence
This constitutes themostextensivemeta-analysison the topic.
Although most of the studies included in our meta-analysis
werecase-control studies, theywereofhigherquality,withNOS
scores ranging between 6 and 9.We addressed the interstudy
heterogeneity, amajor limitation of previous research on this
topic. First, the statistical tests showed no significant hetero-
geneity between the included studies in both our meta-
analysis and subgroup analysis. Second, to account for the
Figure 4. Funnel Plot for Studies on the Association
Between β-HPV and cSCC
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different HPV collection and detection methods, we per-
formed a subgroup analysis restricted to studies that em-
ployed HPV serology. Third, we individually evaluated the
association of each β-HPV type with cSCC. This type-specific
meta-analysis constitutes another major quality of the
evidence presented in this study.
Study Limitations
One limitation of this study is the effect of UV light thatmight
represent a confounder.50 We attempted tominimize this ef-
fect by addressing it in our studyquality assessment. Further-
more,most includedstudieswere case-control studies that re-
cruited from the same latitude level and adjusted for UV
sunlight exposure.
Even though we have found a strong association
between β-HPV and cSCC it is difficult to prove causality as
our analysis is constituted mostly of case-control studies.
However, the findings of 2 large prospective cohort
studies26,27 were in concordance with current evidence sug-
gesting HPV involvement as a causal agent of the initiation
process of cSCC. Moreover, our pooled analysis did not
include every β-HPV type, a limitation that pertains to the
Figure 5. Forest Plot for the SubgroupMeta-analysis: Seroprevalence Only
OR (95% CI)
101.00.1
Cases/Controls No.Study, year Positive, % RR (95% CI)
1.43(1.13-1.82)
1.46 (1.16-1.84)
HPV-5 (I2: 33%)
645/807Bouwes Bavinck et al,24 2010 16.90/9.05 2.05 (1.49-2.82)
173/300Iannacone et al,29 2012 20.23/12.67 1.68 (0.95-2.97)
633/NAAndersson et al,27 2012 10.74/NA 1.20 (0.82-1.75)
663/805Karagas et al,25 2010 6.49/5.09 1.45 (0.90-2.34)
43/77Waterboer et al,23 2008 27.91/28.57 0.60 (0.21-1.75)
39/80Casabonne et al,22 2007 12.82/20.00 0.60 (0.14-2.55)
252/461Karagas et al,21 2006 11.11/6.72 1.80 (1.02-3.17)
160/333Feltkamp et al,11 2003 1.25/0.30 2.60 (0.21-32.83)
150/NAPlasmeijer et al,26 2011 9.33/NA 1.00 (0.54-1.84)
HPV-8 (I2: 63%)
645/807Bouwes Bavinck et al,24 2010 39.53/28.00 1.68 (1.35-2.10)
173/300Iannacone et al,29 2012 36.42/23.00 1.80 (1.14-2.84)
47/46Struijk et al,28 2006 29.79/4.35 9.30 (1.90-45.56)
633/NAAndersson et al,27 2012 23.70/NA 1.00 (0.78-1.27)
150/NAPlasmeijer et al,26 2011 36.67/NA 1.10 (0.80-1.51)
663/805Karagas et al,25 2010 19.16/15.28 1.45 (1.07-1.96)
43/77Waterboer et al,23 2008 37.21/16.88 1.20 (0.51-2.84)
39/80Casabonne et al,22 2007 23.08/20.00 1.10 (0.40-3.01)
252/461Karagas et al,21 2006 16.27/14.75 1.20 (0.80-1.80)
160/333Feltkamp et al,11 2003 4.38/0.30 14.70 (1.60-135.02)
46/84Masini et al,20 2003 56.52/32.14 3.20 (1.30-7.89)
HPV-15 (I2: 56%)
645/807Bouwes Bavinck et al,24 2010 30.39/22.80 1.48 (1.17-1.87)
173/300Iannacone et al,29 2012 28.90/25.33 0.93 (0.58-1.49)
43/47Struijk et al,28 2006 23.26/6.38 3.80 (0.91-15.83)
633/NAAndersson et al,27 2012 20.70/NA 1.10 (0.85-1.42)
150/NAPlasmeijer et al,26 2011 25.33/NA 1.00 (0.68-1.46)
663/805Karagas et al,25 2010 22.02/16.65 1.49 (1.11-2.00)
43/77Waterboer et al,23 2008 41.86/24.68 2.80 (1.10-7.11)
39/80Casabonne et al,22 2007 10.26/18.75 0.50 (0.12-2.06)
252/461Karagas et al,21 2006 10.32/8.89 1.30 (0.77-2.20)
160/333Feltkamp et al,11 2003 4.38/2.10 1.20 (0.40-3.60)
79/84Masini et al,20 2003 62.03/47.62 0.40 (0.19-0.85)
HPV-20 (I2: 38%)
645/807Bouwes Bavinck et al,24 2010 20.00/12.76 1.71 (1.29-2.27)
173/300Iannacone et al,29 2012 29.48/21.00 1.41 (0.88-2.26)
633/NAAndersson et al,27 2012 20.70/NA 1.20 (0.90-1.60)
150/NAPlasmeijer et al,26 2011 11.33/NA 0.60 (0.33-1.10)
633/805Karagas et al,25 2010 19.76/15.16 1.45 (1.08-1.95)
43/77Waterboer et al,23 2008 30.23/29.87 0.90 (0.37-2.20)
39/80Casabonne et al,22 2007 23.08/21.25 1.10 (0.41-2.96)
252/461Karagas et al,21 2006 9.92/6.07 1.70 (0.93-3.10)
160/333Feltkamp et al,11 2003 5.00/2.10 2.20 (0.74-6.58)
HPV-17 (I2: 0%)
1.18 (0.95-1.48)
1.33 (1.08-1.63)
1.42 (1.23-1.64)
645/807Bouwes Bavinck et al,24 2010 31.78/23.54 1.51 (1.20-1.91)
173/300Iannacone et al,29 2012 35.26/25.67 1.59 (1.02-2.48)
633/NAAndersson et al,27 2012 23.06/NA 1.20 (0.90-1.60)
633/805Karagas et al,25 2010 20.21/16.40 1.37 (1.02-1.84)
43/77Waterboer et al,23 2008 46.51/27.27 2.60 (1.02-6.60)
39/80Casabonne et al,22 2007 20.51/15.00 1.40 (0.48-4.06)
Favors Association Favors No Association
The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The diamond represents the pooled OR and 95% CI of the overall population.
The vertical dashed line indicates the overall pooled OR of 1.35. HPV indicates human papillomavirus; NA, not available; OR, odds ratio.
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majority of studies assessing the topic. In addition,
the method of HPV collection in our analysis was not PCR
for HPV DNA from skin biopsy, the gold standard for detec-
tion. However, previous studies7,34 demonstrated that
eyebrow hair DNA and multiplex serology are reliable
substitutes.
Research and Clinical Implications
The concordance between our epidemiological data in
immunocompetent individuals and the molecular plausibil-
ity of type-specific involvement of β-HPV type 5, 8, 15, 17,
20, 24, and 38 in cSCC represents the evidence to strongly
suggest a role for the HPV types in viral oncogenesis
described herein. The associated increased risk of cSCC with
these HPV types (30%-45%), the reported morbidity and
mortality associated with cSCC and the increasing cost of
care, constitute a burden on our health care system. This
highlights the need to develop and test the efficacy of incor-
porating the above mentioned β-HPV subtypes into avail-
able HPV vaccines. Moreover, these efforts could render
HPV vaccinations more widely accepted, possibly increas-
ing the compliance rates for all HPV vaccines. A vaccine that
includes these types of β-HPV will also be a major step
toward precision medicine in the prevention of cSCC
in solid organ transplant recipients, stem cell transplant
recipients, and patients with melanoma undergoing BRAF
inhibitor therapy.
Conclusions
This article represents, to our knowledge, the most extensive
meta-analysis appraising the epidemiological association of
β-HPV subtypes implicated in the pathogenesis of cSCC. This
meta-analysis provides additional evidence of the involve-
ment of β-HPV in the development of cSCC in immunocompe-
tent individuals. Furthermore, this adds precision to the exist-
ingepidemiological findingsbyhighlightingasignificant, type-
specific HPV association,which in turn is in concordancewith
the new arisingmolecular type-specific evidence.
Figure 6. Forest Plot for the SubgroupMeta-analysis: Seroprevalence Only
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Random-effects model using DerSimonian-Laird 1.35 (1.26-1.44)
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The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The diamond represents the pooled OR and 95% CI of the overall population.
The vertical dashed line indicates the overall pooled OR of 1.35. HPV indicates human papillomavirus; NA, not available; OR, odds ratio.
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NOTABLENOTES
Aloe Vera in Dermatology—The Plant of Immortality
Valencia Long, MBBS
Aloe vera, or Aloe barbadensis, is perhaps themost ubiquitous plant in
skincareproductsacross theworldandwasusedeven inancientGreece,
Rome,Babylonia, andChina.Historical evidence suggests that both the
leaf and pulp of this plant have been used extensively to treat derma-
tological ailments and were believed to prevent skin senescence,
acne, psoriasis, relieve pruritus, prevent premature graying of the hair,
improve alopecia, and promote wound healing.1 This Notable Note
addresses the myriad of conditions aloe alleviates and provides a brief
historical perspective of this “plant of immortality.”
During the reign of Emperor Nero, around 50 BC, the Greek physi-
cian Dioscorides cited aloe as being able to alleviate skin irritation, sun-
burn, andacne.Subsequently,Pliny theElder, aphysicianwho lived from
AD 23 to 79, confirmed in his encyclopedia,Natural History, the discov-
eries of Dioscorides.2 While some studies show that aloe vera may
inhibit growth of Staphylococcus aureus, Shigella flexneri, and other
superficialmycoses-causing fungus, others suggest that it is ineffective
in preventing Propionibacterium acnes–induced acne.1
In ancient Egypt, Cleopatra and Nefertiti incorporated aloe as part
of their daily skin and beauty care. The deadwere embalmedwith aloe
vera because of its antibacterial and antifungal properties. It was be-
lieved that in stopping the physical decomposition process, eternal life
could be attained physically and also spiritually.
Aloe’s antiaging and anti-inflammatory effects were well docu-
mented in the Papyrus Eber of 1550 BC. In Sanskrit, the plant is
known as Ghrita-Kumari. Kumar means girl, and it was believed that
this plant provided womanly youthfulness. Modern studies have
shown that aloe gel significantly improves wrinkles and elasticity in
photoaged human skin, increases collagen production in photo-
protected skin, and decreases collagen-degrading MMP-1 gene
expression.1
Alexander theGreatwas thought to have used aloe juice to heal the
war wounds on his warriors. Aloe was so important to Alexander that
he arranged for transportable carts of planted aloe as supplies during
hisnumerousbattle campaigns.Aristotle evenconvinced thegreat con-
queror to capture the island of Socotra specifically to gain possession
of the precious aloe groves—allowing Alexander’s army to acquire
sufficient medication to heal the wounds of entire battalions.3
In modern times, mechanistic studies1 have proven that aloe can
enhancethesynthesisofglycosaminoglycancomponents(hyaluronicacid
and dermatan sulfate) in the matrix of a healing wound to increase the
collagencontentof thegranulation tissueand thedegreeof crosslinking.
While many studies in modern times have validated the positive
effects of aloe, contradictory observations exist for the treatment of
psoriasis. As Pliny and Dioscorides described in ancientmedical texts,2
the true efficacy of aloe vera perhaps also depends on the interplay of
its compounds, its geographic origin, and processing methods.
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